The medical management of human health disorders has taken some interesting twists in direction over the past decade. Cell based therapies have gained traction in the aspiring field of regenerative medicine. Therapeutic correction of genetic defects- through the tinkering efforts of molecular biologists-continue to be hotly pursued despite some alarming setbacks. And in the business of drug development-investments in R and D at the production end of things, coupled with the disturbingly increased financial strains imposed on consumers- a call for creative solutions has led to the generation of several options, many of which will impact the practice of reproductive medicine. So what is looming on the horizon with respect to the next iteration of drugs for managing human infertility-or fertility-for that matter? Ironically, the halcyon days of recombinant gonadotro-pins are yielding to mounting pressures to reduce excessive COH where in appropriate situations patients will likely begin to reap benefits at both the pharmacy desk and their pocketbooks. Meanwhile, natural products like HMG continue to be a mainstay in human ARTs as do drugs like clomid and GnRH agonists and antagonists. Therapeutic pharmacology is aggressively taking aim at "small molecules", which will hopefully bear the fruits of new therapeutic agents based on the massive small molecule library screening activities ongoing within academic institutions and the pharmacological industry. So far, at least to my knowledge, no breakthroughs are in evidence.
展开▼
